Canada - English - Health Canada

homeocan inc. - wyethia helenioides - tablet - 1ch - wyethia helenioides 1ch - homeopathic products

Canada - English - Health Canada

biologische heilmittel heel gmbh - wyethia helenioides - liquid - 10d - wyethia helenioides 10d - homeopathic products

Canada - English - Health Canada

biologische heilmittel heel gmbh - wyethia helenioides - liquid - 4d - wyethia helenioides 4d - homeopathic products

Canada - English - Health Canada

seroyal international inc. - wyethia helenioides - globules - 1x - wyethia helenioides 1x - homeopathic products

United States - English - NLM (National Library of Medicine)

washington homeopathic products - wyethia - to relieve the symptoms of hay fever. indications: wyethia   hay fever if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

United States - English - NLM (National Library of Medicine)

washington homeopathic products - wyethia helenioides - to relieve the symptoms of hay fever. indications: wyethia helenioides hay fever if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

United States - English - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - desvenlafaxine succinate (unii: zb22enf0xr) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - pristiq is indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for antidepressants at 1-844-405-6185. risk summary based on data from published observational studies, exposure to snris, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see warnings and precautions (5.4) and clinical considerations] . there are no published studies on pristiq in pregnant women; however published epidemiologic studies of pregnant women exposed to venlafaxine, the parent compound, have not reported a clear association with adverse developmental outcomes (see data) . there are risks associated with untreated depression in pregnancy and with expos

United States - English - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - effexor xr is indicated in adults for the treatment of: effexor xr is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including effexor xr, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/ . risk summary available data from published epidemiologic studies on venlafaxine use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse fetal outcomes (see data) . available data from observational studies with venlafaxine have identified a potential increased risk for preeclampsia when used during mid to late pregnancy; exposure to snris near delivery may increase the risk for postpartum hemorrhage (see clinical considerations)

United States - English - NLM (National Library of Medicine)

wyeth biopharma division of wyeth pharmaceuticals llc - moroctocog alfa (unii: 113e3z3cjj) (moroctocog alfa - unii:113e3z3cjj) - xyntha, antihemophilic factor (recombinant), is indicated for use in adults and children with hemophilia a (congenital factor viii deficiency) for: xyntha does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease. xyntha is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster proteins. risk summary it is not known whether xyntha can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. animal reproduction studies have not been conducted with xyntha. there is no information available on the effect of factor viii replacement therapy on labor and delivery. xyntha should be used only if clinically indicated. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. risk summary there is no information regarding the presence of xyntha in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for xyntha and any potential adverse effects on the breastfed child from xyntha or from the underlying maternal condition. safety and efficacy with xyntha were evaluated in clinical studies in 68 pediatric subjects <17 years of age (18 subjects aged 12 to <17 years, 50 subjects aged ≤12 years). there were no apparent differences in the efficacy and safety in pediatric subjects as compared to adults [see adverse reactions (6.1) and clinical studies (14) ]. in comparison to the pharmacokinetic parameters reported in adults, children have shorter half-lives, larger volumes of distribution and lower recovery of factor viii after xyntha administration. the clearance (based on per kg body weight) is approximately 40% higher in children. higher or more frequent doses may be required to account for the observed differences in pharmacokinetic parameters [see clinical pharmacology (12.3) ]. clinical studies of xyntha did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. xyntha ® /zin -tha/ [antihemophilic factor (recombinant)] xyntha is supplied as a lyophilized powder. before you can infuse it (intravenous injection), you must reconstitute the powder by mixing it with the liquid diluent supplied. the liquid diluent is 0.9% sodium chloride. reconstitute and infuse xyntha using the infusion set, diluent, syringe, and adapter provided in this kit. please follow the directions below for the proper use of this product. preparation and reconstitution of xyntha preparation reconstitution note: if you use more than one vial of xyntha for each infusion, reconstitute each vial according to steps 1 through 11. note: infusion of xyntha your healthcare provider will teach you how to infuse xyntha yourself. once you learn how to do this, you can follow the instructions in this insert. before xyntha can be infused, you must reconstitute it as instructed above in the preparation and reconstitution of xyntha section. after reconstitution, be sure to look carefully at the xyntha solution. the solution should be clear to slightly opalescent and colorless. if it is not, throw away the solution and use a new kit. use the infusion set included in the kit to infuse xyntha. do not infuse xyntha in the same tubing or container with other medicines. note: additional instructions xyntha is also supplied in kits that have both the xyntha powder and the diluent within single-use prefilled dual-chamber syringes, called xyntha solofuse. if you use one xyntha vial and one of xyntha solofuse for the infusion, reconstitute the xyntha vial and the xyntha solofuse according to the specific directions for that respective product kit. use a separate 10 milliliter or larger luer lock syringe (not included in this kit) to draw back the reconstituted contents of the xyntha vial and xyntha solofuse. use of a xyntha vial kit with a xyntha solofuse kit these instructions are for the use of only one xyntha vial kit and one xyntha solofuse kit. for further information, please contact your healthcare provider or call the medical information department at wyeth pharmaceuticals, 1-800-438-1985. note: dispose of all unused solution and other used medical supplies in an appropriate container. this product's labeling may have been updated. for the most recent prescribing information, please visit www.pfizer.com . license no: 3 lab-0516-9.0

United States - English - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - protonix for delayed-release oral suspension and protonix delayed-release tablets are indicated for: protonix is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of protonix may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. protonix is indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. protonix is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. risk summary available data from published observational studies did not demonstrate an association of major malformations or other adverse pregnancy outcomes with pa